Thursday , November 23 2017
Home / Biosimilars / Results from Late-Stage Study Demonstrate Clinical Equivalence of Boehringer Ingelheim’s Adalimumab Biosimilar Candidate to Humira

Results from Late-Stage Study Demonstrate Clinical Equivalence of Boehringer Ingelheim’s Adalimumab Biosimilar Candidate to Humira

Check Also

Amgen Launches the Enbrel Mini Reusable Autoinjector That is Ergonomically Designed for Patients

THOUSAND OAKS, Calif., Nov. 17, 2017 /PRNewswire/ — Amgen (NASDAQ: AMGN) announced that the ENBREL …